🔴 Chimeric Therapeutics is trading 25% down today after a second dose-limiting toxicity halted its trial

Chimeric Therapeutics is trading 25% down at A$0.01 as investors continue repricing the August 19 clinical setback after a second dose-limiting toxicity stopped enrolment and dosing in its CHM-2101 trial.

• The Board will not progress CHM-2101 in its current form.
• Funding remains uncertain, creditors are under negotiation, and going-concern uncertainty is expected.
• The replacement in-vivo programme remains preclinical and requires additional funding.